This mechanism provides a new multi-target therapeutic strategy based on natural compounds for diabetic nephropathy, expands the clinical application scenarios of PCA, deepens the understanding of the dynamic balance of the GSK3β-Nrf2-ERS network in podocyte injury, and provides a theoretical basis for targeted drug design. This evidence concerns the gene GSK3B and diabetic kidney disease.